EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients



A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients



Transplantation 74(7): 961-966



Background: Basiliximab (Simulect) has been shown to be safe and effective in adult renal transplant recipients, when used in combination with cyclosporine (Neoral) and corticosteroids. We report on the safety and preliminary efficacy of basiliximab in pediatric de novo renal transplant recipients. Methods: This was an open-label, 12-month study of basiliximab in 41 patients (2 cohorts: <9 and 9 to <16 years).

(PDF emailed within 0-6 h: $19.90)

Accession: 010070999

Download citation: RISBibTeXText

PMID: 12394837

DOI: 10.1097/00007890-200210150-00010



Related references

Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids. Transplantation Proceedings 37(2): 672-674, 2005

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction. Journal of Heart & Lung Transplantation 23(2S): S107, February, 2004

Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study. Transplantation Proceedings 38(5): 1301-1306, 2006

Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplantation Proceedings 39(5): 1386-1391, 2007

Results of a 6-month, multicenter, open-label, prospective study concerning efficacy and safety of mycophenolate sodium in de novo kidney transplant recipients. Transplantation Proceedings 39(9): 2730-2732, 2007

OR03-5 A phase 2, multicenter, multiple-dose, open-label, parallel-group, active controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study of ACP-001 in adult patients with Growth Hormone Deficiency (AGHD). Growth Hormone & Igf Research 22: S8-S9, 2012

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78(9): 1332-1340, 2004

An open-label, multicenter study to further characterize the clinical utility and safety of sirolimus in combination with cyclosporine therapy in de novo renal allograft recipients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 912A, September, 2001

Multicenter, open-label study of the long-term safety and efficacy of RAD used in combination with Simulect , corticosteroids and Neoral in renal transplantation 6 Month results. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 685A, September, 2000

A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus. Transplantation Proceedings 44(1): 144-146, 2012

Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatric Transplantation 5(4): 297-301, 2001

An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Liver Transplantation and Surgery 4(5): 410-415, 1998

Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplantation Proceedings 33(7-8): 3172-3173, 2001

Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units. Transplantation Proceedings 35(5): 1697-1698, 2003

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Journal of Clinical Psychiatry 72(9): 1270-1276, 2011